Safety and efficacy of PD-1 inhibitors plus tyrosine kinase inhibitors combination therapy in patients with advanced hepatocellular carcinoma combined with hyperbilirubinemia: a retrospective cohort study
Combination therapy demonstrated favorable safety and tolerability among patients with HCC combined with hyperbilirubinemia. Patients who experienced a rapid decline in TBIL levels during the early phase of treatment with PD-1 inhibitors and TKIs were observed to derive clinical benefits. Early initiation of aggressive interventions aimed at reducing TBIL levels is recommended to optimize treatment outcomes.
Authors
- Yingjuan Shen
- Yan‐Mei Jiao (ORCID: https://orcid.org/0000-0002-2556-326X)
- Qin Qiu
- Fanping Meng (ORCID: https://orcid.org/0000-0001-8094-1107)
- Shida Pan
- Siyu Wang (ORCID: https://orcid.org/0000-0002-7603-2012)
- Yilin Wang (ORCID: https://orcid.org/0000-0002-8455-390X)
- Fusheng Wang (ORCID: https://orcid.org/0000-0002-9369-9361)
- Luo Yang (ORCID: https://orcid.org/0000-0003-0148-8987)
- Xiaomeng Liu (ORCID: https://orcid.org/0000-0001-7420-715X)
- Jiahe Tian (ORCID: https://orcid.org/0009-0002-4365-0540)
- Fengyi Li (ORCID: https://orcid.org/0000-0001-9943-0091)
- Junqing Luan
- Jianing Wang (ORCID: https://orcid.org/0009-0002-5203-8767)
- Yingying Yu (ORCID: https://orcid.org/0009-0007-4227-333X)
Institutions
- University of Science and Technology of China (CN)
- Capital Medical University (CN)
- Peking University (CN)
- Chinese PLA General Hospital (CN)
- Beijing Ditan Hospital (CN)
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1530477
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Innovative Research Group Project of the National Natural Science Foundation of China
- Beijing Municipal Science and Technology Commission